Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Crop Protection And Acacia Strike Deal

Premium

RICHMOND, Calif.--Acacia Biosciences here and Novartis Crop Protection announced the signing of a profiling agreement to utilize Acacia's patented Genome Reporter Matrix to aid in the selection and optimization of lead compounds for crop-protection products. Under the agreement, Acacia will provide chemical and biological profiles on a class of Novartis's compounds for an undisclosed fee.

The patented technology incorporates a microarray that measures changes in gene expression with a comprehensive database of expression profiles and a set of software tools that facilitate the comparison of profiles and the discovery of new genes and targets. Acacia said the first generation of this technology is based on the fully sequenced yeast genome.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.